Prudential Financial Inc. lowered its stake in shares of Steris Corp. (NYSE:STE) by 41.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 248,790 shares of the company’s stock after selling 176,608 shares during the period. Prudential Financial Inc. owned approximately 0.29% of Steris Corp. worth $17,104,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in STE. Palisade Capital Management LLC NJ purchased a new position in shares of Steris Corp. during the first quarter valued at $1,839,000. Champlain Investment Partners LLC raised its position in shares of Steris Corp. by 1.1% in the first quarter. Champlain Investment Partners LLC now owns 466,540 shares of the company’s stock valued at $33,148,000 after buying an additional 5,250 shares during the period. JPMorgan Chase & Co. raised its position in shares of Steris Corp. by 43.9% in the first quarter. JPMorgan Chase & Co. now owns 616,502 shares of the company’s stock valued at $43,802,000 after buying an additional 187,935 shares during the period. Columbia Partners L L C Investment Management purchased a new position in shares of Steris Corp. during the first quarter valued at $1,593,000. Finally, Massmutual Trust Co. FSB ADV purchased a new position in shares of Steris Corp. during the first quarter valued at $250,000. 91.58% of the stock is owned by institutional investors and hedge funds.
Steris Corp. (NYSE:STE) traded down 0.12% during midday trading on Thursday, hitting $73.07. The company’s stock had a trading volume of 64,897 shares. The company’s 50 day moving average price is $71.26 and its 200 day moving average price is $70.18. The firm has a market cap of $6.29 billion, a P/E ratio of 41.97 and a beta of 1.16. Steris Corp. has a 12 month low of $61.38 and a 12 month high of $78.77.
Steris Corp. (NYSE:STE) last posted its earnings results on Tuesday, August 9th. The company reported $0.79 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.02. Steris Corp. had a net margin of 5.52% and a return on equity of 10.72%. The business earned $638.40 million during the quarter, compared to the consensus estimate of $639.04 million. During the same quarter in the previous year, the firm posted $0.62 EPS. The firm’s revenue was up 45.1% on a year-over-year basis. Analysts expect that Steris Corp. will post $3.90 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 27th. Stockholders of record on Tuesday, August 30th were given a dividend of $0.28 per share. This is an increase from Steris Corp.’s previous quarterly dividend of $0.25. The ex-dividend date of this dividend was Friday, August 26th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.53%. Steris Corp.’s payout ratio is presently 68.71%.
Several equities analysts have weighed in on the company. Zacks Investment Research raised Steris Corp. from a “sell” rating to a “hold” rating in a report on Thursday. Northcoast Research raised Steris Corp. from a “neutral” rating to a “buy” rating in a report on Friday, June 3rd.
In other news, CEO Walter M. Rosebrough, Jr. sold 15,000 shares of the business’s stock in a transaction on Wednesday, August 17th. The shares were sold at an average price of $71.08, for a total transaction of $1,066,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Sudhir K. Pahwa sold 1,028 shares of the business’s stock in a transaction on Friday, August 26th. The shares were sold at an average price of $70.13, for a total transaction of $72,093.64. The disclosure for this sale can be found here. Insiders own 2.52% of the company’s stock.
Steris Corp. Company Profile
STERIS Corporation (STERIS) is a provider of infection prevention and other procedural products and services. The Company is focused on healthcare, pharmaceutical and research. The Company operates through three business segments: Healthcare, Life Sciences and STERIS Isomedix Services. The Healthcare segment provides surgical, sterile processing, infection prevention and gastrointestinal solutions.
Receive News & Ratings for Steris Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris Corp. and related companies with MarketBeat.com's FREE daily email newsletter.